Recent advances in the biology of heavy-ion cancer therapy

重粒子線がん治療の生物学の最近の進展

浜田 信行*; 今岡 達彦*; 増永 慎一郎*; 尾方 俊至*; 岡安 隆一*; 高橋 昭久*; 加藤 宝光*; 小林 泰彦; 大西 武雄*; 小野 公二*; 島田 義也*; 手島 昭樹*

Hamada, Nobuyuki*; Imaoka, Tatsuhiko*; Masunaga, Shinichiro*; Ogata, Toshiyuki*; Okayasu, Ryuichi*; Takahashi, Akihisa*; Kato, Takamitsu*; Kobayashi, Yasuhiko; Onishi, Takeo*; Ono, Koji*; Shimada, Yoshiya*; Teshima, Teruki*

Superb biological effectiveness and dose conformity represent a rationale for heavy-ion therapy, which has thus far achieved good cancer controllability while sparing critical normal organs. Immediately after irradiation, heavy ions produce dense ionization along their trajectories, cause irreparable clustered DNA damage, and alter cellular ultrastructure. These ions, as a consequence, inactivate cells more effectively with less cell-cycle and oxygen dependence than conventional photons. The modes of heavy ion-induced cell death/inactivation include apoptosis, necrosis, autophagy, premature senescence, accelerated differentiation, delayed reproductive death of progeny cells, and bystander cell death. This paper briefly reviews the current knowledge of the biological aspects of heavy-ion therapy, with emphasis on the authors' recent findings. The topics include (1) repair mechanisms of heavy ion-induced DNA damage, (2) superior effects of heavy ions on radioresistant tumor cells (intratumor quiescent cell population, TP53-mutated and BCL2-overexpressing tumors), (3) novel capacity of heavy ions in suppressing cancer metastasis and neoangiogenesis, and (4) potential of heavy ions to induce secondary (especially breast) cancer.